Sofosbuvir as backbone of interferon free treatments  by Bourlière, Marc et al.
RS
M
D
a
A
R
A
A
K
D
D
H
I
N
R
S
S
d
i
g
i
i
s
w
S
p
c
s
w
D
p
h
o
u
c
a
w
h
h
1Digestive and Liver Disease 46 (2014) S212–S220
Contents lists available at ScienceDirect
Digestive  and  Liver  Disease
journa l h om epage: www.elsev ier .com/ locate /d ld
eview  Article
ofosbuvir  as  backbone  of  interferon  free  treatments
arc  Bourlière ∗, Valèrie  Oules,  Christelle  Ansaldi,  Xavier  Adhoute,  Paul  Castellani
epartment of Hepato-Gastroenterology, Hôpital Saint Joseph, Marseilles, France
 r  t  i  c  l e  i  n  f  o
rticle history:
eceived 15 September 2014
ccepted 26 September 2014
vailable online 6 November 2014
eywords:
AAs
a  b  s  t  r  a  c  t
Sofosbuvir  is the  ﬁrst-in-class  NS5B  nucleotide  analogues  to be launched  for  hepatitis  C virus  (HCV)  treat-
ment.  Its  viral  potency,  pangenotypic  activity  and  high  barrier  to  resistance  make  it the  ideal  candidate  to
become  a  backbone  for several  IFN-free  regimens.  Recent  data  demonstrated  that  sofosbuvir  either with
ribavirin  alone  or in  combination  with  other  direct-acting  antivirals  (DAAs)  as  daclatasvir,  ledipasvir  or
simeprevir  are  able  to  cure  HCV  in  at least  90%  or  over  of  patients.  Treatment  experienced  genotype  3
population  may  remain  the  most  difﬁcult  to treat population,  but ongoing  DAA  combination  studies  willaclatasvir
CV
FN-free
S5B nucleotide inhibitors
ibavirin
imeprevir
ofosbuvir
help  to ﬁll  this  gap.  Safety  proﬁle  of sofosbuvir  or combination  with  other  DAAs  is good.  Resistance  to
sofosbuvir  did not  appear  as  a signiﬁcant  issue.  The  rationale  for using  this  class  of  drug and  the  available
clinical  data  are  reviewed.
© 2014  Editrice  Gastroenterologica  Italiana  S.r.l.  Published  by Elsevier  Ltd.  
Open access under CC BY-NC-ND license.Treatment of hepatitis C virus (HCV) infection has improved
ramatically in the last four years. The launch of the ﬁrst direct act-
ng antiviral (DAA) agents in 2011, boceprevir and telaprevir, ﬁrst
eneration protease inhibitors (PIs), in combination with pegylated
nterferon and ribavirin (PR) was a major step forward in improv-
ng HCV treatment [1–6]. However, this progress was hampered by
etbacks from toxicity to resistance [7]. In 2014, three new DAAs
ere approved and launched in a number of Western countries.
ofosbuvir is the ﬁrst-in-class, potent nucleotide analogue (NA)
olymerase inhibitor which acts as a chain terminator within the
atalytic site of the NS5B polymerase. FDA and EMA  have approved
ofosbuvir for pangenotypic HCV treatment either in combination
ith PR or in IFN-free combinations either with ribavirin or other
AAs. Simeprevir is a second wave ﬁrst generation NS3/4A PI with
otent antiviral activity in genotype 1, 2, 4, 5 and 6. FDA and EMA
ave approved this agent as part of a combination therapy for naïve
r treatment experienced genotype 1 patients and also allows its
se in combination with other DAAs. Daclatasvir is a potent ﬁrst-in-
lass NS5A inhibitor that has been shown to have a pangenotypic
ctivity. EMA  has validated the use of daclatasvir in combination
ith other agents including sofosbuvir for the treatment of chronic
epatitis C. Moreover, a large number of DAA-based regimens are in
∗ Corresponding author.
E-mail address: mbourliere@hopital-saint-joseph.fr (M.  Bourlière).
ttp://dx.doi.org/10.1016/j.dld.2014.09.024
590-8658/© 2014 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. Opthe late stage of clinical development and others are in the pipeline
[7,8]. This new step forward demonstrates that IFN-free DAA regi-
mens with a shortened duration of treatment are able to improve
sustained virological response (SVR) rate to over 90%, thus raising
the possibility of curing HCV.
1. IFN-free DAAs-based regimen, is a backbone needed?
The  better understanding of the viral life cycle has allowed the
development of DAAs targeting different parts of the viral genome
[9]. These novel agents inhibit the virus more potently than inter-
feron but are able to generate more or less rapidly resistant variants
with continuous treatment [10]. With single-drug treatment, a
resistant variant with good ﬁtness may  outgrow the wild-type virus
within a few days and become the predominant viral species in the
population thus leading to treatment failure. The ﬁrst approach
in dealing with DAA resistance was to associate DAAs with PR.
Peg interferon stimulates a host of genes, known as interferon-
stimulated genes, which have antiviral activities and constitute an
effective backbone to prevent the development of DAA resistance
especially if the DAA’s antiviral potency is high [11].
When moving to IFN-free regimens we  may need a new back-
bone with a high barrier to resistance and potent antiviral efﬁcacy
in order to use this compound with only one other class of DAAs,
thus reducing drug–drug interactions and allowing short treatment
duration. An alternative to a backbone is the use of an association of
en access under CC BY-NC-ND license.
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ultiple low barriers to resistance and antiviral potent DAAs. This
ffective strategy is, however, currently limited to genotype 1 and
 patients [12–17].
The  barrier to resistance may  be either genetic such that more
han one nucleotide change is needed for resistance to emerge; it
ay  be due to high drug exposures that inhibit low-level resistant
irus or it may  be related to the poor ﬁtness of the resistant variant.
herefore, a high barrier to resistance is needed for any DAA to
ecome a backbone for HCV treatment [18].
Among the different classes of DAAs, NA NS5B polymerase
nhibitors appear to be the preferred backbones for IFN-free treat-
ent. This is due to the fact that the most common resistant
ariant for NA NS5B polymerase inhibitors is a substitution of ser-
ne to threonine at position 282 (S282T) in the active site of the
NA-dependant RNA polymerase (RdRp). However, this variant is
xtremely unﬁt with an 11-fold reduction in the efﬁciency of the
olymerase enzyme leading to a replication rate of 3–15% that of
ild type virus in in vitro assays [19,20]. The S282T variant either
an pre-exist before treatment in some patients or may  be selected
uring therapy, but its poor ﬁtness does not allow this variant
o expand to any signiﬁcant degree. This is the reason why  it is
ery infrequently found in patients who fail NA therapy, and why
etreatment with NA for longer durations is feasible and can lead
o SVR [21].
Another important requirement for any DAA to become a back-
one in an IFN-free regimen is to have a potent antiviral activity,
hich is essential to achieve SVR and to overcome modest resis-
ance. Ideally, this compound should also have a pangenotypic
ctivity in order to be given in all HCV regimens. NA NS5B poly-
erase inhibitors, as a class, fulﬁl all these characteristics.
Among currently available or nearly available DAAs, the other
olecule which fulﬁls nearly the same requirements is the sec-
nd generation PI MK5172 (MSD, White house, USA). This newer
I has higher barriers to resistance and broader genotypic coverage
han ﬁrst generation PIs (although again not covering genotype 3
CV) that make it a potentially good backbone candidate for HCV
reatment [22].
Host  targeting agents (HTAs) inhibit a host function necessary
or HCV replication. Because they target the host, HTAs are usually
onsidered to have a high barrier to resistance and a pangenotypic
ctivity and therefore, can be used as a backbone in HCV treat-
ent. Two classes of HTAs have been clinically developed so far, the
yclophilin inhibitors and miR-122 antagonists. Alisporivir (Novar-
is, Basel, Switzerland) is the cyclophilin inhibitor with the most
dvanced clinical development [23]. During the last two  years it
as been put on clinical hold due to a fatal case of acute pancreatitis
hat occurred in combination with PR. It is now back in devel-
pment for all genotypes [24]. Alisporivir has demonstrated high
arrier to resistance in IFN-free regimens in genotype 2 or 3 patients
23]. However, the antiviral potency is lower than that observed
ith DAAs. The miR-122 antagonist miravirsen (Santaris Pharma,
openhagen, Denmark) has demonstrated a potent antiviral activ-
ty (reduction up to 3 logs IU/ml) after two weeks of intravenous
nfusions in genotype 1 patients [25]. However, there are some con-
erns about the hypothetic long-term hepatic effects of inhibiting
iR-122 and the risk of steatohepatitis, ﬁbrosis and hepatocellular
arcinoma.
The other alternative targets for HCV speciﬁc therapy, such as
CV entry inhibitors or NS4B function inhibitors could theoretically
ave a pangenotypic activity with a good barrier to resistance. How-
ver, none of the HCV entry inhibitor candidates have moved into
ate clinical development, and they have demonstrated only mild
ntiviral potency. Among NS5B function inhibitors, silibinin is, up
o now, the only compound that has been studied with encouraging
esults despite the possible occurrence of mutations in NS4B that
onfer partial resistance to silibinin in vitro [26].r Disease 46 (2014) S212–S220 S213
In summary, in IFN-free regimens, a pangenotypic backbone
appears to be necessary and NA NS5B polymerase inhibitors appear
to be the best class of DAAs to fulﬁl this role.
2. Nucleotide analogues NS5B polymerase inhibitors: good
candidates  to act as backbones in IFN-free combinations
NAs bind to the NS5B active sites, causing chain termination
and/or an increased number of errors when incorporated into a
growing RNA chain. The NS5B’s active site being well conserved,
NAs tend to have a similar efﬁcacy across all genotypes and present
the highest barrier to resistance of all DAAs to date. In contrast,
NNAs have shown a restricted spectrum of activity against the
various HCV genotypes. They are mainly active against HCV GT-
1 and present the lowest barrier to resistance. NS5B NAs appear,
therefore, to be among the most promising pangenotypic drugs.
Nucleosides are sugars bound to one of the bases used for DNA or
RNA synthesis, while nucleotides are nucleosides with the addition
of a phosphate group [26,27]. A vast majority of nucleotide ana-
logues are prodrugs that are linked to a molecule that is cleaved
mainly by hepatic enzymes to increase delivery of the nucleotide
monophosphate to the hepatocyte. Within the cells, nucleotides
or nucleosides need phosphorylation to be transformed into their
active forms. HCV RdRp as a false substrate incorporates the
triphosphate form during RNA replication leading to chain termi-
nation and inhibition of viral replication [28]. However, natural
nucleotides are also required by the host cell for replication. Even
if NAs are designed to serve as speciﬁc substrates for viral poly-
merase, they may  also be incorporated by host polymerases and
therefore lead to toxicity. This pattern was observed with ﬁaluri-
dine, with HBV NAs and with early HIV NAs (D4T, DDI) but up to
now it has not been observed in HCV NAs.
However, other toxicities have been reported with some of the
ﬁrst HCV NAs. All guanosine NAs were discontinued during phase
2a due to gastrointestinal toxicities for valopicitabine, lymphopenia
for R-1626, hepatotoxicity for PSI-938 and cardiac toxicity for BMS-
986094.
Mericitabine is the only cytidine NA developed so far. In triple
therapy for 24 weeks with ribavirin and danoprevir, a ritonavir
boosted PI, mericitabine was  shown to be moderately potent in
genotype 1b naïve patients with 71% of SVR, and inefﬁcient in geno-
type 1a naïve patients with 26% of SVR [29]. In quadruple therapy
for 12 or 24 weeks with ribavirin, danoprevir and setrobuvir, a
NS5B NNA, mericitabine was potent in genotype 1b patients with
96% of SVR, but less potent in genotype 1a patients [30]. Therefore,
given the lower potency in genotype 1a patients, it is unlikely that
mericitabine will play a major role in HCV therapy in the future.
Among  the uridine NAs, sofosbuvir is the only drug approved by
both FDA and EMA. VX-135 is another uridine NA in development.
In combination with ribavirin VX-135 demonstrated viral potency
in genotype 1 patients [31]. However, based on liver enzyme ele-
vations seen at the dose of 400 mg  in 3 out of 10 patients, the drug
was placed on partial clinical hold by FDA limiting further studies
to a maximal dose of 200 mg.  In combination for 12 weeks with
daclatasvir, an NS5A inhibitor, VX-135 at the dose of 200 mg  daily
was able to reach 91% of SVR in a small pilot study [32]. Other uri-
dine NAs with good proﬁles that are actually in the pre-clinical
stage are IDX-21437 or ACH-3422 [33].
Therefore, to date and for at least one or two  years, sofosbu-
vir will remain the only NS5B NA available in clinical practice.
Sofosbuvir is a prodrug of 2′deoxy-2′-ﬂuoro-2′-C-methyluridine
monophosphate, which must be phosphorylated twice after enter-
ing the hepatocyte [34]. The drug is absorbed intact through the
gastrointestinal tract with no signiﬁcant food effect and results in
a high liver exposure. Sofosbuvir is largely excreted through the
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phase II study [44]. All patients achieved SVR in the FDC regimen214 M. Bourlière et al. / Digestive an
idney. Importantly, sofosbuvir does not interact with cytochrome
450 system or any other major drug metabolizing enzymes and
herefore has no or few drug-drug interactions, allowing easier
reatment in patients on other medications such as transplanted
r co-infected patients. Sofosbuvir has so far been administered
o more than 5000 patients, including patients with advanced cir-
hosis, HIV co-infection, patients awaiting liver transplantation and
atients with severe post-transplant recurrence, with a clean safety
roﬁle [35]. The efﬁcacy and the safety of sofosbuvir have led
o its rapid clinical development as a backbone of IFN-free DAA
egimens.
. Clinical data with sofosbuvir in IFN-free regimens
The clinical data on sofosbuvir as part of IFN-free regimens
ccording to genotype and treatment status are summarized in
ables 1 and 2.
.1.  Genotype 1
.1.1.  Sofosbuvir plus ribavirin
This  combination has been evaluated in genotype 1 patients in
everal small studies with conﬂicting and relatively disappoint-
ng results. In the initial ELECTRON study, sofosbuvir 400 mg  daily
ith weight-based ribavirin was given to 25 naïve non-cirrhotic
enotype 1 patients for 12 weeks. All patients suppressed virus
n treatment and 84% achieved SVR [36]. In the next QUANTUM
tudy, 38 naïve genotype 1 patients with mild ﬁbrosis were ran-
omized to receive 12 or 24 weeks of the same regimen. Overall
VR rate was 50% (53% for 12 weeks and 47% for 24 weeks) [37].
he discrepancy between the two studies may  be related to a lower
ercentage of patients with favourable IL28B CC genotype in the
UANTUM study. In the SPARE study, sofosbuvir and ribavirin were
iven for 24 weeks with either a weight-based ribavirin dose or a
ower 600 mg  daily dose in a hard-to-treat population, mainly over-
eight African Americans with more advanced ﬁbrosis. The study
ighlights the importance of the ribavirin dose when it is associated
ith sofosbuvir alone as the SVR rate was 68% in the weight-based
roup versus 48% in the low ribavirin dose group [38]. Moreover,
elapse was more frequent among patients with advanced ﬁbro-
is and all cirrhotic patients relapsed. In the PHOTON-1 study, 114
aïve genotype 1 HIV/HVC co-infected patients were treated for
4 weeks with sofosbuvir and weight-based ribavirin. SVR rate
as 76%. This may  be partly explained by the baseline charac-
eristics of the population with mainly white patients with mild
brosis (5 patients had cirrhosis) and the high proportion (26%) of
avourable IL28B CC genotype [39]. In a phase 2 open-label study
n patients awaiting liver transplantation (LT), 61 cirrhotic patients
ith a Child Pugh score ≤7, with a median MELD score of 8 (6–14)
eceived up to 48 weeks of sofosbuvir and weight-dosed ribavi-
in while on the waiting list before LT (median duration 17 weeks)
40]. 73% of the patients were genotype 1, 76% of the patients were
L28B non-CC and 75% of the patients had failed treatment on PR.
orty-four patients underwent LT and of these, 41 (93%) had HCV
NA < 25 IU/ml before LT. Of these, 39 patients reached 12 weeks
f follow-up post transplantation and 64% achieved SVR. Safety
nd tolerance of this regimen were good. Most frequently reported
dverse events were mild and only one patient discontinued treat-
ent due to ribavirin-induced anaemia.
In treatment-experienced patients with failure to PR, the ini-
ial ELECTRON study demonstrated a disappointing 10% SVR rate in
he ten patients who received sofosbuvir and weight-dosed riba-
irin for 12 weeks [36]. However, in the post transplant study,
3 genotype 1 patients were treated for 24 weeks with sofosbu-
ir and ribavirin and 70% achieved SVR [41]. One hundred andr Disease 46 (2014) S212–S220
ﬁve  genotype 1 patients, who  where non-responders or relapsers
after a previous treatment with sofosbuvir or GS-0938 with or
without ribavirin, were retreated with sofosbuvir and ribavirin
for 24 weeks in the QUANTUM study and 65% achieved SVR
[37].
In summary, the sofosbuvir - ribavirin combination in geno-
type 1 patients appears to be a suboptimal regimen, and should
therefore be considered as an alternative approach for patients who
cannot take PEG-IFN and when other DAAs are not available. The
combination of sofosbuvir with another class of DAAs, either PIs or
NS5A inhibitors, gives more impressive SVR results and should be
preferred, when available, in genotype 1 patients.
3.1.2. Sofosbuvir plus protease inhibitors
The combination of sofosbuvir (400 mg  daily) with the second-
wave, ﬁrst generation PI simeprevir (150 mg  daily) with or without
weight-dosed ribavirin for 12 or 24 weeks was evaluated in the
COSMOS trial [42]. One hundred and sixty seven genotype 1
patients were treated. The study was divided into two  cohorts: (1)
80 patients prior null responders to PR with ﬁbrosis stage F0-2 and
(2) 87 patients treatment naïve or prior null responders to PR with
ﬁbrosis stage F3-4.
Of  the 39 treatment-naïve F3-4 patients, 95% achieved SVR,
regardless of whether the regimen was  given 12 or 24 weeks and
whether it included ribavirin. Among prior null responders to PR, in
cohort 1, the SVR rate with 12 or 24 weeks with or without ribavirin
was similar and high across all groups (Table 1). In cohort 2, among
the 47 prior null responders to PR patients with advanced ﬁbrosis
or cirrhosis the SVR rate was  again high, over 90% across all groups
(Table 1). SVR was similar regardless of whether the regimen was
given for 12 or 24 weeks and whether it included ribavirin. Across
both cohorts SVR was  similar according to subtype, 95% in geno-
type 1b and 92% in genotype 1a. Moreover, regarding the inﬂuence
of Q80K mutation at baseline on SVR rate in genotype 1a patients,
58 patients harboured this mutation at baseline across all groups
and 88% (51/58) achieved SVR compared with 94% (68/72) in those
without this mutation. Based on this study, 12 weeks of sofosbu-
vir and simeprevir without ribavirin appear to be a very efﬁcacious
regimen with a good safety proﬁle in genotype 1 patients. Whether
or not genotype 1a patients with baseline Q80K mutation should
be treated with another combination with NS5A inhibitors remains
an open issue.
3.1.3.  Sofosbuvir plus NS5A inhibitors
The combination of sofosbuvir with NS5A inhibitors is a very
attractive combination due to the potency and the pangenotypic
activity of both molecules and the high barrier to resistance of NAs.
Sofosbuvir was  initially evaluated in combination with
daclatasvir (60 mg  daily) with or without ribavirin for 12 or 24
weeks in 126 naïve genotype 1 patients with mainly mild ﬁbro-
sis [43]. All patients treated 24 weeks achieved SVR. Among those
treated 12 weeks, the SVR was 100% without ribavirin and 95% with
ribavirin with no on-treatment breakthrough. This combination for
24 weeks was also evaluated in 41 patients with mild or moderate
ﬁbrosis who had failed prior triple therapy with either boceprevir
or telaprevir. All patients achieved SVR.
These results were therefore conﬁrmed when sofosbuvir was
combined with ledipasvir (90 mg  daily) in a ﬁxed-dose combina-
tion (FDC) pill. The FDC regimen in genotype 1 naïve patients was
initially evaluated with or without ribavirin for 12 or 8 weeks in thewith ribavirin for 8 weeks, while in both arms with FDC regimen
without ribavirin for 8 or 12 weeks one patient relapsed, therefore
95% SVR was achieved. Similar results were obtained in treatment-
experienced patients, who  had failed triple therapy with PIs, treated
M. Bourlière et al. / Digestive and Liver Disease 46 (2014) S212–S220 S215
Table  1
Summary of clinical trial data with sofosbuvir in IFN-free regimens for genotype 1 patients.
Population Study (Ref.) N. patients Treatment regimen Duration (wk) SVR12 (%)
Genotype 1 naïve ELECTRON [36] 25 SOF + RBV 12 84%
QUANTUM [37] 38 SOF + RBV 12 vs 24 12w: 53%
24w: 47%
SPARE  [38] 50 SOF + RBV
WB or LDRBV
24 WB:  68%
LD:  48%
PHOTON [39]
HIV  + HCV
114 SOF + RBV 24 76%
COSMOS [42]
Cohort  2 F3/F4
39 SOF + SIM ± RBV 12  or 24 95%
12w = 24w
AI1444-40 [43] 126 SOF + DCV ± RBV 12 or 24 12w: SOF/DCV: 98%
SOF/DCV/RBV: 95%
24w:  SOF/DCV: 100%
SF/DCV/RBV:  100%
ELECTRON  [51] 25 SOF + LDV + RBV 6  68%
LONESTAR [44] 60 SOF + LDV ± RBV 8 or 12 8w SOF/LDV: 95%
8w  SOF/LDV/RBV: 100%
12w  SOF/LDV: 95%
ION-1  [45] 865 SOF + LDV ± RBV 12  or 24 12w: SOF/LDV: 99%
SOF/LDV/RBV: 97%
24w:  SOF/LDV: 98%
SOF/LDV/RBV: 99%
ION-3  [46] 647 SOF + LDV ± RBV 8 or 12 8w:  SOF/LDV: 94%
8w:  SOF/LDV/RBV: 93%
12w: SOF/LDV: 95%
ELECTRON-2  [21] 20  cirrhotic CPT B SOF + LDV 12 65%
ERADICATE [48]
HIV  + HCV
50 SOF + LDV 12 100% interim results
SYNERGY  [52] 60 SOF + LDV ± GS-9669
(NNI) or GS-9451 (PI)
6  or 12 12w: SOF/LDV: 100%
6w:  SOF/LDV/9669:
90%
6w:SOF/LDV/9451:100%
New  combination [50] 55 SOF + GS-5816 (25 or
100  mg)
12  25 mg:  96%
100  mg: 100%
Genotype 1
treatment-experienced
ELECTRON [36] 10 SOF + RBV 12 10%
QUANTUM [37]
NR  to DAA regimen
including  SOF or
GS-0938  ± RBV
105 SOF + RBV 24 65%
Post transplant study
[41]
33  SOF + RBV 24 70%
COSMOS [42]
Cohort  1 F0/F2
80 SOF + SIM ± RBV 12 or 24 12w SOF/SIM: 93%
SOF/SIM/RBV: 96%
24w  SOF/SIM: 93%
SOF/SIM/RBV: 79%
COSMOS  [42]
Cohort  2 F3/F4
47 SOF + SIM ± RBV 12 or 24 12w: SOF/SIM: 93%
SOF/SIM/RBV: 93%
24w:  SOF/SIM: 100%
SOF/SIM/RBV: 93%
A1444-40  [43]
PI  failure
41 SOF + DCV ± RBV 24 SOF/DCV: 100%
SOF/DCV/RBV: 100%
LONESTAR  [44]
PI  failure
40 SOF + LDV ± RBV 12 SOF/LDV: 95%
SOF/LDV/RBV: 100%
ELECTRON  [51] 70 SOF + LDV ± RBV or
GS-9669 (NNI)
12 F4: SOF/LDV: 70%
F4:  SOF/LDV/RBV: 100%
F3/4:  SOF/LDV/RBV:
100%
SOF/LDV/9669: 100%
ION-2  [47]
Including PI failure
440 (231PI failure) SOF + LDV ± RBV 12 or 24 12w: SOF/LDV: 94%
SOF/LDV/RBV: 96%
24w:  SOF/LDV: 99%
SOF/LDV/RBV: 99%
ELECTRON2  [21] SOF
failure
19  SOF + LDV + RBV 12 100%
SYNERGY [49]
SOF/RBV  relapsers
14 SOF + LDV 12 100%
S ibavir
I
w
f
n
wOF, sofosbuvir; RBV, ribavirin; WB,  weight-based ribavirin dose; LDRBV, low dose r
.  second generation); PR, peg-interferon plus ribavirin.ith FDC regimen with (100% SVR) or without ribavirin (95% SVR)
or 12 weeks. In order to clarify the duration of treatment and the
eed for ribavirin with the FDC regimen, three large phases III trial
ere conducted. ION-1 and ION-3 studies were conducted in 1512in; SIM, simeprevir; DCV, daclatasvir; LDV, ledipasvir (NS5A I); GS-5816 (new NS5Anaïve genotype 1 patients. In ION-1 study, 865 patients were ran-
domized to receive FDC regimen with or without ribavirin for 12
or 24 weeks [45]. The rate of SVR in all treatment groups was 97%
or higher regardless of whether the regimen was  given for 12 or
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Table  2
Summary of clinical trial data with sofosbuvir in IFN-free regimens for genotypes 2–6 patients.
Population Study (Ref.) N. patients Treatment regimen Duration (wk) SVR12 (%)
Genotype 2 naïve ELECTRON [36] 4 SOF + RBV 12 4/4: 100%
FISSION  [53] 137  SOF + RBV 12w vs. PR 24w 12 24 SOF/RBV: 97%
PR:  78%
POSITRON [54] 109 SOF + RBV 12 93%
VALENCE [55] 32 SOF + RBV 12 97%
PHOTON [39]HIV + HCV 26 SOF + RBV 12 88%
AI1444-40 [43] 26 SOF + DCV ± RBV 24 96%
New  combination [50] 21 SOF + GS-5816 (25 or 100 mg) 12 25 mg: 91%
100  mg:  100%
Genotype 2 treatment-experienced FUSION [54] 68 SOF + RBV 12 or 16 12w: 86%
F4:  60%
16w: 94%
F4:  78%
PHOTON  HIV + HCV 24  SOF + RBV 12 92%
VALENCE [55] 41 SOF + RBV 12 90%, F4: 78%
Genotype  3 naïve ELECTRON [36] 6 SOF + RBV 12 6/6: 100%
FISSION  [53] 359 SOF + RBV 12w vs. PR 24w 12 24 SOF/RBV: 56%
PR:  62%
POSITRON [54] 98 SOF + RBV 12 61%
VALENCE [55] 105 SOF + RBV 24 94%, F4: 92%
PHOTON  [39]HIV + HCV 42 SOF + RBV 12 67%
AI1444-40 [43] 18 SOF + DCV ± RBV 24 94%
ELECTRON-2 [21] 51 SOF + LDV ± RBV 12 SOF/LDV: 64%
SOF/LDV/RBV: 100%
New  combination [50] 54 SOF + GS-5816 (25 or 100 mg) 12 25 mg: 93%
100  mg:  93%
Genotype 3 treatment-experienced FUSION [54] 127 SOF + RBV 12 or 16 12w: 30%
F4:  19%
16w: 62%
F4:  61%
PHOTON  HIV + HCV 17  SOF + RBV 12 94%
VALENCE [55] 145 SOF + RBV 24 79%, F4: 62%
Genotype  4 naïve HCV GT-4 [58] 28 SOF + RBV 12 or 24 12w: 79%
24w: 100%
New  combination [50] 14 SOF + GS-5816 (25 or 100 mg) 12 25 mg: 100%
100  mg:  86%
Genotype 4 treatment-experienced HCV GT-4 [58] 32 SOF + RBV 12 or 24 12w: 59%
24w: 87%
Genotype  5 naïve New combination [50] 1 SOF + GS-5816 (25 mg) 12 1/1: 100%
Genotype  6 naïve New combination [50] 9 SOF + GS-5816 (25 or 100 mg) 12 25 mg: 100%
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4 weeks and whether it included ribavirin. The rates of treatment
iscontinuation were higher in the groups treated for 24 weeks
han in the groups treated for 12 weeks. Similarly the rates of side
ffects were higher in the groups that received ribavirin than in
he corresponding group that did not. Moreover, SVR rates were
niform, regardless of the baseline characteristic of the patients. In
articular, the presence of cirrhosis had no marked effects on SVR
ate (97–100%) and safety proﬁle. The ION-1 study showed that 12
eeks FDC is highly effective in genotype 1 naïve patients without
ny additional beneﬁt in extending treatment duration or addition
f ribavirin.
In the ION-3 study 647 naïve-genotype 1 patients without cir-
hosis were randomized to receive FDC regimen with or without
ibavirin for 8 weeks or FDC regimen for 12 weeks [46]. The rates
f SVR in the three treatment groups were high, over 90% (94% FDC
 weeks, 93% FDC + ribavirin 8 weeks and 95% in FDC 12 weeks).
he results of non-inferiority analysis suggested that adding riba-
irin to the 8 weeks FDC regimen or extending duration from 8
o 12 weeks did not result in improved SVR rates. SVR rates were
niform regardless of the baseline characteristics historically asso-
iated with a poor response to PR. Although relapse was more
ommon among patients who received 8 weeks of treatment (20
s. 3), no baseline characteristics or on-treatment variables could100  mg:  100%
I); GS-5816 (new NS5A I. second generation); PR, peg-interferon plus ribavirin.
be  identiﬁed associated with relapse. This study suggests that only
8 weeks of FDC may  be sufﬁcient for the treatment of naïve non-
cirrhotic genotype 1 patients.
In the ION-2 study, 440 treatment-experienced genotype 1
patients, including 231 patients who  had failed triple therapy with
PIs, were randomized to receive FDC regimen with or without
ribavirin for 12 or 24 weeks [47]. Similarly to ION-1 study, the
rates of SVR in all treatment arms were between 94 and 99%.
They were similar with widely overlapping conﬁdence intervals
regardless of treatment duration or use of ribavirin. However, this
study was not powered to compare responses to regimens with
or without ribavirin or to 12 or 24 weeks of treatment. In cir-
rhotic patients SVR rate was  modestly lower in patients treated
for 12 weeks (86% FDC and 82% FDC plus ribavirin) than in those
without cirrhosis (95 and 100% respectively), whereas in the 24
weeks treatment groups, SVR rates were similar in patients with
cirrhosis (99%) and in those without cirrhosis (100%). No base-
line factors or on-treatment viral kinetics during the ﬁrst 2 weeks
of treatment was  predictive of relapse in patients with cirrho-
sis treated for 12 weeks. Overall these results suggest that in
treatment experienced patients, non-cirrhotic patients may  ben-
eﬁt from 12 weeks of FDC without additional beneﬁt of extending
treatment duration or addition of ribavirin, whereas in cirrhotic
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atients 24 weeks of FDC may  be more suitable in order to maximize
VR.
FDC regimen was also evaluated in ﬁfty naïve HIV/HCV geno-
ype 1 patients leading to SVR in all patients treated for 12 weeks
o far [48]. In advanced cirrhotic patients CPT B the same regi-
en led to 65% of SVR suggesting that longer treatment duration is
uitable in this situation [21]. In patients who previously failed or
elapsed to sofosbuvir containing regimen, all patients achieved
VR with FDC regimen with or without ribavirin for 12 weeks
21,49].
Sofosbuvir was recently associated in a phase 2 study with a
ew, very potent and pan genotypic NS5A inhibitor (GS-5816).
reliminary results showed that at the dose of 100 mg  of GS-
816 combined with sofosbuvir for 12 weeks all genotype 1 naïve
atients achieved SVR [50].
.1.4. Sofosbuvir in combination with multiple DAAs
The rationale for such a combination is to maximize, if possi-
le, SVR rate in a difﬁcult-to-treat population or to try to shorten
reatment duration. In the ELECTRON study, seventy treatment-
xperienced patients with advanced ﬁbrosis or cirrhosis were
andomized to receive FDC with or without ribavirin or FDC plus
S-9669, a NS5B NNI, for 12 weeks [51]. SVR rate was  70% among
he cirrhotic patients treated with FDC, although SVR was  achieved
n all patients treated either with FDC plus ribavirin or GS-9669. The
YNERGY phase II study evaluated FDC in combination with GS-
669 or GS-9451, a second wave PI for 6 weeks in naïve genotype
 patients [52]. All twenty patients treated with FDC plus GS-9651
chieved SVR and 18/20 (90%) achieved SVR in the group treated
ith FDC plus GS-9669. These preliminary data suggest that adding
ther potent DAAs to the FDC could either maximize the virological
esponse in most difﬁcult-to-treat patients or allow the shortening
f treatment duration.
.2.  Genotype 2
SVR  in genotype 2 patients differs markedly to that in genotype
 patients with PR regimen but the difference is even more obvi-
us with IFN-free DAA regimens. Therefore, SVR data need to be
nalysed separately.
.2.1.  Sofosbuvir plus ribavirin
After  the initial ELECTRON study, in which all four naïve geno-
ype 2 patients achieved SVR [36], three large phase III trials
FISSION, POSITRON, VALENCE) conﬁrmed that in naïve genotype 2
atients this regimen for 12 weeks achieved SVR in more than 93%
f the patients (Table 2) [53–55]. Moreover, the randomized con-
rolled FISSION study demonstrated that sofosbuvir plus ribavirin
or 12 weeks was signiﬁcantly superior compared to the standard
R regimen for 24 weeks [53]. Across the three studies, thirty naïve
irrhotic patients were treated and 28 (93%) achieve SVR with a 12
eek regimen. Based on the results of these trials, both FDA and
MA have approved sofosbuvir and ribavirin for 12 weeks in all
enotype 2 naïve patients. The same results were obtained in the
IV/HCV co-infected trial in which SVR rate was 88% in genotype 2
atients [39].
In  the FUSION study, sixty-eight genotype 2 patients who failed
rior PR regimen were randomized to receive sofosbuvir plus riba-
irin for 12 or 16 weeks [54]. Among the forty-nine non-cirrhotic
atients SVR rate was similar in both arms: 96% for 12 weeks and
00% for 16 weeks respectively. On the other hand, among the 19
irrhotic patients, the SVR rate was 60% for 12 weeks and 78% for
6 weeks, suggesting that longer treatment duration may  improve
VR. However, the small number of patients limits the possibility
f drawing a strong conclusion, moreover, in the VALENCE study,r Disease 46 (2014) S212–S220 S217
in  which genotype 2 patients were treated for 12 weeks, the SVR
rate among the nine treatment-experienced patients with cirrhosis
was 78% [55].
3.2.2.  Sofosbuvir plus NS5A inhibitors
Sofosbuvir was evaluated in combination with daclatasvir
(60 mg  daily) with or without ribavirin in 26 naïve genotype 2
patients, four of whom had cirrhosis [43]. SVR rate was 96%. Ribavi-
rin did not seem to necessary to the achievement of SVR, however,
the number of patients is too small to draw any signiﬁcant con-
clusion. No data are available for genotype 2 patients with the
combination of sofosbuvir plus ledipasvir.
Sofosbuvir was also evaluated in combination with GS-5816 in
21 genotype 2 naïve-patients [50]. All patients but one (who died
during follow-up) achieved SVR.
In conclusion, in genotype 2 patients either treatment-naïve any
ﬁbrosis stage or treatment-experienced without cirrhosis, sofos-
buvir plus ribavirin for 12 weeks achieved a very high SVR and is
the recommended regimen worldwide. For treatment-experienced
patients with cirrhosis, this regimen is suboptimal and treat-
ment may  be extended up to 16 weeks or longer [56]. Another
option, that needs to be studied, is to use the combination of
sofosbuvir plus NS5A inhibitors (daclatasvir or others) for 12 or
24 weeks.
3.3. Genotype 3
Genotype  3 patients appear to be the most difﬁcult to cure pop-
ulation in IFN-free regimen with the three drug currently available
[56].
3.3.1. Sofosbuvir plus ribavirin
After  the initial ELECTRON study, in which all six naïve genotype
3 patients achieved SVR [36], three large phase III trials (FISSION,
POSITRON, VALENCE) were conducted in naïve genotype 3 patients
(Table 2) [53–55]. The randomized controlled FISSION study
conducted among three hundred and ﬁfty-nine naïve patients
demonstrated similar SVR rates in patients treated with sofosbuvir
plus ribavirin for 12 weeks compared to the standard PR regi-
men for 24 weeks, 56% and 62% respectively [53]. In the POSITRON
study, ninety eight naïve genotype 3 patients achieved an SVR rate
of 61% [54] and similar results were found in the HIV/HCV co-
infected study with a 67% SVR rate [39]. Across the two  studies,
ﬁfty-two naïve cirrhotic patients were treated and sixteen (31%)
achieved SVR with a 12 week regimen. Therefore, the VALENCE
study was  conducted in one hundred and ﬁve naïve patients treated
with sofosbuvir and ribavirin for 24 weeks [55]. 94% of the non-
cirrhotic patients and 92% of the thirteen cirrhotic patients achieved
SVR. Based on the results of these trials, both FDA and EMA  have
approved sofosbuvir and ribavirin for 24 weeks in all genotype 3
naïve patients.
The  randomized FUSION study conducted among 127 geno-
type 3 patients who failed prior PR regimen demonstrated a poor
SVR rate of 30% for those treated for 12 weeks and 62% for those
treated for 16 weeks [54]. Treatment duration was  extended to
24 weeks in the VALENCE study in one hundred and forty-ﬁve
patients. SVR was achieved in 79% of the patients: the rate was
87% in non-cirrhotic patients and 62% in the forty-seven cirrhotic3.3.2.  Sofosbuvir plus NS5A inhibitors
Sofosbuvir was evaluated in combination with daclatasvir
(60 mg  daily) with or without ribavirin in eighteen naïve geno-
type 3 patients, two  of whom had cirrhosis [43]. SVR rate was
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4%. Ribavirin did not seem to add anything towards SVR; how-
ver, the number of patients was too small to draw any signiﬁcant
onclusion.
Sofosbuvir plus ledipasvir in FDC with or without ribavirin for 12
eeks was evaluated in ﬁfty-one naïve genotype 3 patients includ-
ng 8 patients with cirrhosis. 64% of patients treated with sofosbuvir
nd ledipasvir achieved SVR, whereas all those treated with FDC
lus ribavirin achieved SVR [21].
Sofosbuvir was also evaluated in combination with GS-5816 (25
r 100 mg  daily) in ﬁfty-four genotype 3 naïve patients [50]. 93% of
hese patients achieved SVR.
In conclusion, in genotype 3 patients either treatment-naïve any
brosis stage or treatment-experienced without cirrhosis, sofosbu-
ir plus ribavirin for 24 weeks achieved a very high SVR rate and is
he recommended regimen worldwide. For treatment-experienced
atients this regimen is suboptimal and other options need to be
tudied e.g. a combination of sofosbuvir with daclatasvir or other
S5A inhibitor such as ledipasvir, or others, for 12 or 24 weeks.
ngoing studies will hopefully discover the optimal treatment for
hese patients. Another option, already explored in an observa-
ional study in patients who  relapsed after sofosbuvir and ribavirin,
s treatment with sofosbuvir and PR for 12 weeks, which was shown
o achieve SVR in 93% of non-cirrhotic patients and 88% of cirrhotic
enotype 3 patients [57].
.4.  Genotype 4
Few  data are available for this population. In a small study,
onducted in Egyptian patients treated in the USA with sofosbu-
ir and ribavirin for 12 or 24 weeks, SVR was achieved in 79% of
he fourteen treatment-naïve patients treated for 12 weeks and
n all the fourteen treatment-naïve patients treated for 24 weeks
58]. Among treatment-experienced patients, 59% of the seventeen
atients treated 12 weeks and 87% of the ﬁfteen patients treated
or 24 weeks achieved SVR [58]. Moreover, all of the seven cirrhotic
atients treated 24 weeks achieved SVR.
Fourteen treatment-naïve patients were treated with sofosbu-
ir plus GS-5816 (25 or 100 mg  daily) for 12 weeks in a small
ilot trial [50]. All, except one patient lost to follow-up, achieved
VR.
Based on this small dataset sofosbuvir plus ribavirin for 24
eeks may  be recommended in genotype 4 patients. However,
ther combinations with sofosbuvir and daclatasvir or simeprevir
eed to be studied due to the efﬁcacy of these drugs for genotype 4
nd ongoing studies will again clarify the optimal management of
his population.
.5. Genotypes 5 and 6
We  have few data for this population with sofosbuvir and PR
or 12 weeks, and there is a lack of data regarding sofosbuvir plus
ibavirin in this population. In the NEUTRINO study, all seven geno-
ype 5 or 6 treatment-naïve patients treated with sofosbuvir and
R for 12 weeks achieved SVR [53]. In a small study one geno-
ype 5 and nine genotype 6 treatment-naïve patients were treated
ith sofosbuvir plus GS-5816 for 12 weeks and all achieved SVR
50].
. Resistance
Resistance does not appear to be a signiﬁcant issue with
ofosbuvir-containing regimens due to the high barrier to resis-
ance of the molecule. In the LONESTAR study, one patient who
elapsed after 8 weeks of FDC was found to harbour both an
S5A resistant mutation (L31M and Y93H) and the S282T signature
ofosbuvir resistant mutation [44]. The L31M mutation was alreadyr Disease 46 (2014) S212–S220
present  prior to commencing therapy. Due to its poor ﬁtness
the frequency of the S282T mutant decreased within two weeks.
Retreatment of this patient with FDC plus ribavirin for 24 weeks
achieved SVR. Since this initial observation, at least eighty-ﬁve
patients who have relapsed with a sofosbuvir-containing regimen
have been retreated with an IFN free sofosbuvir-containing regi-
men achieving a high rate of SVR [21,57]. In these two  studies, the
S282T resistant mutant was  not detected, either due to the poor
ﬁtness of the variant or a lack of sensitivity of the methods used
to detect the variant. Anyhow, of the nineteen genotype 1 patients
who relapsed with sofosbuvir plus ribavirin for 12 weeks (n = 10),
FDC for 6 weeks (n = 8) or sofosbuvir plus ribavirin and GS-9669
for 12 weeks (n = 1), all achieved SVR after 12 weeks of FDC with
ribavirin [21]. In another observational study, sixty-six genotype
2 or 3 patients who  relapsed after sofosbuvir and ribavirin were
retreated with either sofosbuvir plus ribavirin for 24 weeks (n = 40)
or sofosbuvir plus PR for 12 weeks (n = 26) [57]. 63% of the patients
treated with sofosbuvir and ribavirin and 92% of those treated with
sofosbuvir and PR achieved SVR. All these data demonstrate that a
sofosbuvir resistant mutant is really not a signiﬁcant issue as long
as we can retreat patients with a combination in which sofosbuvir
is associated with any DAA with activity against the S282T resistant
mutant.
5. Factors predicting failure for sofosbuvir containing
treatments
The high success rates achieved with sofosbuvir make identiﬁ-
cation of predictive factors of failure rather difﬁcult. For the combi-
nation of sofosbuvir plus ribavirin the lower SVR rate observed in
genotype 3 patients showed that previous treatment failure on PR,
cirrhosis and slow viral decline during the ﬁrst two weeks of treat-
ment are associated with treatment failure on sofosbuvir [55]. Once
a second DAA is added to sofosbuvir, even baseline characteristics
such as cirrhosis become less and less important. In the ION-2 study,
only cirrhosis was  predictive of failure for the 12 week regimen, but
all cirrhotic patients achieved SVR with FDC for 24 weeks.
6.  Conclusion
The launch of sofosbuvir is a major advance in HCV treatment.
The potency, high barrier to resistance, pangenotypic activity,
once-daily dosage, good safety proﬁle and the limited drug-drug
interactions make this compound an ideal backbone for IFN-free
regimens. The data already collected has demonstrated that sofos-
buvir plus ribavirin treatment in genotype 2, 3 and 4 allows the
achievement of SVR at least in 90% of the patients. Sofosbuvir in
combination with either NS5A inhibitors (daclatasvir or ledipasvir)
or PIs (simeprevir) achieves SVR in more than 95% of genotype
1 patients. Hopefully ongoing studies will ﬁll the remaining
gap for treatment-experienced genotype 3 patients with DAA
combinations. Moreover, shorter treatment duration (down to
6 weeks) becomes possible using the combination of sofosbuvir
with multiple DAAs. Compliance to drug regimens will be a major
issue if we want to avoid relapse. However, at the current price,
treatment with DAAs, including sofosbuvir, will not be a viable
option for many HCV infected people living in countries with
strong economic constraints. Therefore, all efforts should be made
to reduce the cost of such therapies so as to be able to extend
treatment to the greatest number of patients.
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